Ocular Paraneoplastic Syndromes

• Main Authors: Joanna Przeździecka-Dołyk, Anna Brzecka, Maria Ejma, Marta Misiuk-Hojło, Luis Fernando Torres Solis, Arturo Solís Herrera, Siva G. Somasundaram, Cecil E. Kirkland, Gjumrakch Aliev
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Biomedicines
• Subjects: cancer-associated retinopathy; melanoma-associated retinopathy; cancer-associated cone dysfunction; paraneoplastic syndromes; vitelliform maculopathy; optic neuritis
• Online Access: https://www.mdpi.com/2227-9059/8/11/490

Ocular-involving paraneoplastic syndromes present a wide variety of clinical symptoms. Understanding the background pathophysiological and immunopathological factors can help make a more refined differential diagnosis consistent with the signs and symptoms presented by patients. There are two main pathophysiology arms: (1) autoimmune pathomechanism, which is presented with cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), cancer-associated cone dysfunction (CACD), paraneoplastic vitelliform maculopathy (PVM), and paraneoplastic optic neuritis (PON), and (2) ectopic peptides, which is often caused by tumor-expressed growth factors (T-exGF) and presented with bilateral diffuse uveal melanocytic proliferation (BDUMP). Meticulous systematic analysis of patient symptoms is a critical diagnostic step, complemented by multimodal imaging, which includes fundus photography, optical coherent tomography, fundus autofluorescence, fundus fluorescein angiography, electrophysiological examination, and sometimes fundus indocyjanin green angiography if prescribed by the clinician. Assessment of the presence of circulating antibodies is required for diagnosis. Antiretinal autoantibodies are highly associated with visual paraneoplastic syndromes and may guide diagnosis by classifying clinical manifestations in addition to monitoring treatment.